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Abstract
Background Implantable cardioverter-defibrillators (ICDs)
are widely used for the prevention of sudden cardiac death.
At present, both clinical benefit and cost-effectiveness of
ICD therapy in primary prevention patients are topics of
discussion, as only a minority of these patients will even-
tually receive appropriate ICD therapy.
Methods/design The DO-IT Registry is a nationwide
prospective cohort with a target enrolment of 1,500 pri-
mary prevention ICD patients with reduced left ventricular
function in a setting of structural heart disease. The pri-
mary outcome measures are death and appropriate ICD
therapy for ventricular tachyarrhythmias. Secondary out-
come measures are inappropriate ICD therapy, death of
any cause, hospitalisation for ICD related complications
and for cardiovascular reasons. As of December 2016, data
on demographic, clinical, and ICD characteristics of 1,468
patients have been collected. Follow-up will continue up
A complete list of investigators in the DO-IT Registry is provided
in the online supplementary material.
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to 24 months after inclusion of the last patient. During
follow-up, clinical and ICD data are collected based on the
normal follow-up of these patients, assuming ICD interro-
gations take place every six months and clinical follow-up
is once a year. At baseline, the mean age was 66 (standard
deviation [SD] 10) years and 27% were women.
Conclusion The DO-IT Registry represents a real-world
nationwide cohort of patients receiving ICDs for primary
prevention of sudden cardiac death with reduced left ven-
tricular function in a setting of structural heart disease. The
registry investigates the efficacy of the current practice and
aims to develop prediction rules to identify subgroups who
will not (sufficiently) benefit from ICD implantation and to
provide results regarding costs and budget impact of tar-
geted supply of primary preventions ICDs.
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Background
Since its introduction in 1980, the implantable cardioverter-
defibrillator (ICD) has become a generally accepted ther-
apy for the prevention of sudden cardiac death (SCD)
[1]. Its efficacy was demonstrated in both primary and
secondary prevention settings [2–8]. Current international
guidelines consider primary prevention ICD implantation
as a class I indication in patients with New York Heart
Association (NYHA) class II or III heart failure with is-
chaemic or non-ischaemic aetiology and left ventricular
dysfunction (left ventricular ejection fraction (LVEF) of
35%). A class I indication is also recommended for
patients with an LVEF 30% and NYHA I functional
capacity [9, 10].
At present, both clinical benefit and cost-effectiveness of
ICD therapy in patients with a primary prevention indica-
tion of SCD are being discussed. During mid-term follow-
up, approximately two thirds of primary prevention ICD
patients will never receive appropriate therapy for ventric-
ular arrhythmias [3, 11–13]. They remain at risk of inap-
propriate shocks and device complications [14–16], which
may impair recipients’ quality of life [17]. Furthermore,
primary prevention randomised control trials (RCTs) were
designed and started enrolling patients in the late nineties
of the previous century. Both treatment of acute myocardial
infarction (primary percutaneous intervention as opposed to
thrombolysis) and treatment of heart failure have changed
considerably. Today, the question arises whether primary
prevention patients will be subject to the same number of
Table 1 Inclusion and Exclusion Criteria
Inclusion Criteria
1 ICD implantation for primary prevention of sudden car-
diac death
2 LVEF 35% and NYHA  III or LVEF 30% and
NYHA I
3 Life expectancy ≥1 year
4 ≥40 days after myocardial infarction
5 ≥90 days after revascularisation procedure
6 Optimal pharmacological heart failure treatment
Exclusion criteria
1 Secondary prevention
2 ICD generator replacement
3 Inability or unwillingness to provide valid informed con-
sent
ICD implantable cardioverter-defibrillator, LVEF left ventricular
ejection fraction, NYHA New York Heart Association
appropriate shocks and will experience a similar relative
risk reduction as patients in these ‘older’ RCTs.
Additionally, there is the ongoing debate whether LVEF
values and NYHA functional classes are sufficiently accu-
rate selection criteria for prognostic stratification of SCD
risk. Consequently, there is a strong need to improve the
current selection criteria for primary prevention ICD treat-
ment in this setting [18–23]. In Europe alone, two prospec-
tively designed cohort studies for improved risk stratifica-
tion are ongoing [24, 25].
Cost-effectiveness studies show a wide variation in ben-
efit, raising doubt about the efficiency, also regarding costs,
of ICD therapy. ICD therapy appears to be only cost-effec-
tive in selected patient groups and seems to be related to the
number of risk factors present for SCD [22, 26–31]. Risk
stratification before ICD implantation is important from
both a medical and an economic standpoint.
The DO-IT Registry aims to prospectively register the
efficacy of implantation of primary prevention ICDs in or-
der to develop prediction rules to identify subgroups who
will not, or not yet, sufficiently or not at all, benefit from
ICD implantation for primary prevention of SCD within two
years of follow-up. What constitutes ‘sufficiently’ will be
defined in a joint effort with a Dutch convenience sample of
ethicists, patient representatives, cardiologists, health care
insurers, health care policymakers, and key opinion leaders.
Additionally, we aim to assess the costs and budget impact
of targeted supply of ICD implantation in primary preven-
tion patients. This article provides an overview of the DO-
IT Registry design, a cohort description and describes the
planned statistical analyses.
Methods
Design and study population
Since September 2014, the DO-IT Registry documents the
current nationwide practice of ICD implantation in the pri-
mary prevention of SCD with reduced left ventricular func-
tion in a setting of structural heart disease. We planned to
collect data on demographic, clinical, and ICD characteris-
tics of 1,500 consecutively recruited patients in all 28 ICD
implanting centres in the Netherlands. Currently, we are
collecting follow-up data up to 24 months after inclusion
of the last patient. The inclusion and exclusion criteria are
shown in Tab. 1. The inclusion criteria are based on current
guidelines (e. g. before 2014) for primary prevention ICD
implantation [9, 10]. The LVEF assessment method was at
the discretion of the local centre. The registry has been ap-
proved by the institutional review boards of all participating
hospitals.
576 Neth Heart J (2017) 25:574–580
Data collection
Cardiologists, electrophysiologists, biostatisticians and
health economists have jointly defined the relevant data
set, in view of existing literature on possible predictors
for SCD. Electronic case report forms (e-CRFs) were gen-
erated using an open source web-based software platform
OpenClinica [32] in compliance with good clinical practice.
By randomly generating a unique identification number,
the anonymity of the patient is maintained. Data of the
patient are collected from medical records and entered into
the eCRF. All participating sites access the registry via
a personal password protected login procedure and can
only access the records of the patients of their own centre.
We provided the participating centres with a sequential
set of instructions for data entry and offered a training, if
needed.
Baseline and follow-up data
We collected baseline data on demographics, medical his-
tory and diagnostics, as well as implantation and device
data. We collected clinical and ICD follow-up data, based
on the normal follow-up of these patients assuming ICD
interrogations take place every six months and clinical fol-
low-up is once a year. Every six months, we register oc-
currence of ventricular arrhythmias and data regarding ICD
therapies. ICD therapy is defined as anti-tachycardia pacing
(ATP) and defibrillator shocks. During clinical follow-up,
medical history, functional status, cardiovascular hospital-
isations and performed procedures and diagnostics of the
past year are entered into the registry. In addition, the par-
ticipating hospitals report adverse events, defined as ICD
related complications and deaths of any cause. Events such
as death, arrhythmias, cardiovascular hospitalisations, car-
diac interventions, diagnostic procedures and laboratory pa-
rameters between last follow-up visit and death are docu-
mented. Medical documentation around the time of death
and ICD interrogations are collected, whenever possible.
A more detailed list of the collected parameters is provided
in the online supplementary material.
Data and adverse event management
Verification rules and edit checks have been built into the
system to validate completeness, accuracy and consistency
of the dataset. Data quality is also maintained by online and
on-site monitoring and continuous assessment of data qual-
ity during the export of datasets to statistical packages for
subsequent analysis. A monitor plan is used which describes
whether outcomes and variables need to be monitored en-
tirely. This decision depends on the expected role of the
variable in the prediction models, expected frequency of
mistakes and the time needed to monitor the variable. The
site investigator is required to maintain adequate records
to ensure the manner in which the registry is conducted is
well documented. The investigator should keep the records
on file for a period of time specified by local law for the
preservation of hospital documents. If requested, the inves-
tigator supplies the monitor with any required data.
A steering committee, represented by cardiologists of the
participating hospitals, is responsible for the scientific in-
tegrity and the way that the study is conducted and advises
the registry coordinating centre, when needed. A clinical
event committee, consisting of independent cardiologists,
assesses all ICD delivered therapies by analysing stored
electrograms. The committee also determines whether
deaths are of cardiac origin.
Outcomes
The primary outcome measures of the DO-IT Registry are
death and appropriate ICD therapy for ventricular tachy-
cardia (VT) or ventricular fibrillation. Secondary outcome
measures are inappropriate ICD therapy, death of any cause,
hospitalisation for ICD related complications and cardio-
vascular reasons.
Sample size/power
The registry has a target enrolment of 1,500 patients with
a follow-up of at least two years. Based on the latest RCT’s
and literature [3, 8] we expect to observe 150 (10%) patients
with appropriate shocks. In combination with 150 fatalities
(5% per year), these are sufficient to develop prediction
rules.
Data analysis
Research aim 1: prediction rules
The incidence for the outcomes of appropriate ICD ther-
apy and death are illustrated by Kaplan-Meier curves. Cox
regression models with baseline characteristics of patients
are developed to predict the outcomes of death or appro-
priate ICD therapy over time, considering the competing
risk. The risk models will be developed according to the
methods that have been used in the paper on the widely
accepted ‘MADIT-II risk score’ for primary therapy with
an ICD [33]. First, we will develop a model with impor-
tant baseline characteristics, selected from previous publi-
cations on ICD mortality risk stratification and appropriate
ICD therapy. We will consider age, gender, body mass in-
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Fig. 1 Flowchart of study
participants
LVEF left ventricular ejection fraction, PCI percutaneous coronary intervention, NYHA New York Heart Association, 
AMI acute myocardial infarction, CABG coronary artery bypass grafting.
*Preliminary data as of February 13, 2017.
Eligible patients: n=1,619 Refused to participate: n=69
Totally included: n=1468*
Reasons for exclusion: n=82
• Secondary prevention (n=46)
• LVEF >45% (n=18)
• Generator replacement (n=9)
• Other (n=9)
Included clinically relevant: n=153
• LVEF >30% and NYHA 1 (n=78)
• PCI <90 days (n=35)
• LVEF >35% - 45% (n=20)
• CABG <90 days (n=8)
• <40 days after AMI (n=5)
• NYHA IV (n=3)
• PCI <90 days and <40 days after AMI (n=3)
• LVEF >30% and PCI <90 days (n=1)
Initially included: n=1,550
dex, LVEF, NYHA class, prior (<1-year) heart failure hos-
pitalisation, history of atrial fibrillation and non-sustained
VT, renal function, diabetes mellitus, smoking history, pul-
monary disease and electrocardiographic parameters. Next,
we will identify further factors, such as events during fol-
low-up (complications and appropriate shock), that might
improve prediction of the primary outcomes in exploratory
analyses. The validity of the resulting predictor sets will be
assessed by bootstrapping. A total of 200 bootstrap regres-
sion analyses will be performed for internal cross valida-
tion. The predictive values of the prediction models will be
quantified using c-statistics.
Research aim 2: economic evaluation
A cost-minimisation analysis and a budget impact of tar-
geted supply of ICD implantation will be performed. This
economic evaluation will compare targeted supply of ICD
implantation based on new prediction rules with current
practice as reflected in the DO-IT Registry. Targeted sup-
ply, however, is not registered; no ICD implantation is with-
held from patients who meet the current guidelines. That
is why we are not able to observe what would have hap-
pened to these patients had they not received an ICD. To
circumvent the missing data, the economic evaluation will
be conducted as a modelling study, and assuming that not
performing unnecessary ICD implantations does not affect
health outcomes, only costs, except for temporal implanta-
tion related complications. These assumptions are realistic,
but depend on the quality of the prediction rules. That is
why we will develop prediction rules which can be applied
in a way that will minimise the number of false negative
predictions. Further details regarding the cost-minimisation
and budget impact analysis are provided in the online sup-
plementary material.
Study population
Between September 10th, 2014 and May 13th, 2016, 1,619
patients were assessed for eligibility. A flowchart of the
study participants is presented in Fig. 1. Sixty-nine patients
refused to participate. Data of 1,550 patients were initially
entered into the registry. However, 82 patients were ex-
cluded because they did not meet the inclusion criteria for
various reasons. Although 153 patients did not fully meet
the inclusion criteria, we decided that these patients should
remain in the registry because they received their ICD in
context of primary prevention with a reduced LVEF in a set-
ting of structural heart disease and were assumed to be
a clinical relevant subgroup. Therefore, 1,468 patients in
total were included in the DO-IT Registry.
Baseline characteristics
The baseline characteristics are presented in Tab. 2. Over-
all, 1,468 patients received their first ICD (single-chamber
or dual-chamber), subcutaneous ICD (S-ICD) or cardiac
resynchronisation therapy defibrillator (CRT-D) for primary
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Table 2 Comparison of patient characteristics of DO-IT Registry (date) with ICD arms of MADIT II and SCD-HeFT Trial
Patient characteristics DO-IT (n = 1,461a) DO-IT (n = 1,308, 153
patients excluded)
SCD-HeFT
(n = 829)
MADIT II
(n = 742)
Age (years)
Mean (SD) 66 (10) 66 (10) 64 (10)
Median (IQR) (68) (60–73) (68) (60–73) 60 (52–68)
Men (%) 73 72 77 84
LVEF
Mean (SD) 26 (6) 26 (6) 23 (5)
Median (IQR) 27 (21–30) 26 (21–30) 24 (19–30)
NYHA
I (%) 14 9 35
II (%) 61 65 70 35
III (%) 22 23 30 25
(%) <1 5
Unknown (%) 3 3
Ischaemic cardiomyopathy (%) 56 54 52 100
Diabetes (%) 27 27 31 33
Hypertension (%) 43 43 55 53
Atrial fibrillation (%) 30 31 17 9
Data are presented as mean (standard deviation) or median (25th–75th percentiles)
DO-IT Dutch Outcome in ICD therapy,ICD implantable cardioverter-defibrillator, SCD-HeFT Sudden Cardiac Death in Heart Failure Trial,
MADIT II Multicentre Automatic Defibrillator Implantation Trial-II, IQR interquartile range, LVEF left ventricular ejection fraction, NYHA New
York Heart Association
aPreliminary data as of February 13, 2017.
prevention of SCD (32%, 16%, 9% and 43%, respectively).
Seventy-three percent of patients were men and the mean
age at implantation was 66 (SD 10) years. The mean LVEF
was 26% and more than half of the patients (61%) expe-
rienced NYHA class II heart failure symptoms. Most pa-
tients, 56%, had ischaemic heart disease. The remaining
641 (44%) patients were considered non-ischaemic.
Discussion
In this article, we describe the design, cohort and planned
analysis of the DO-IT Registry. This nationwide prospec-
tive registry aims to identify patients who will benefit most,
or who will benefit the least, from ICD implantation. It
further aims to assess the costs and budget impact of tar-
geted supply of primary prevention ICDs. This is one of
the largest prospective cohorts of primary prevention ICD
patients, with a nationwide participation of all ICD implant-
ing centres in the Netherlands. This research reflects current
clinical practice and will provide real-world outcomes in the
general population.
There are some differences between the baseline char-
acteristics of the DO-IT patients and the patients included
in the largest RCTs, MADIT II [8] and SCD-HEFT [3]
(Tab. 2). Overall, DO-IT patients are older, more often fe-
male, and have higher LVEF. More patients have NYHA II
symptomatic heart failure compared with MADIT II pa-
tients.
We enrolled 153 patients who did not fully meet the
ACC/AHA/ESC Class I indication for primary prevention
ICD implantation. The DO-IT Registry was designed to
capture all primary prevention ICD patients. If the reason
for ICD implantation was primary prevention for reduced
LVEF in the setting of structural heart disease, patients were
not excluded from the registry. Prior analyses of other pri-
mary prevention ICD registries also show that a proportion
of patients do not meet trial inclusion criteria [34, 35]. Fur-
ther analyses of these patients could clarify the event rate
in this group, and might elucidate common risk factors that
led to the decision to implant an ICD without a clear Class I
indication.
Study limitations
As expected, the registry has limitations [36, 37]. First,
there is no control group with eligible patients who did
not receive an ICD. However, the findings can be evaluated
within the context of the previous RCTs or other registries.
Second, there is a possibility of underreporting or misre-
porting, because data in registries are often collected more
passively and monitored less strictly compared with RCTs.
Third, patients should be included consecutively. However,
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the inclusion of patients was not controlled. For instance,
sites may have been unable to enrol all eligible patients or
simply have forgotten to register one. In addition, physi-
cians may have been more likely to exclude patients with
uncertain benefit of ICD implantation, which results in se-
lection bias. However, we built in quality and control checks
and online and on-site monitoring to ensure that the data is
representative and of adequate quality.
Some recent articles are not discussed in the content of
this paper because they were published later than the setup
of the DO-IT Registry [38–40]. However, these studies also
emphasise the need for improved selection of patients for
primary ICD therapy since most patients do not experience
benefit.
Although the DO-IT Registry is designed and funded for
an initial follow-up duration of two years after inclusion of
the last patient, other studies show that patients might ben-
efit from primary prevention ICD therapy with follow-up
longer than two years [11, 41]. However, additional post
cohort projections and hypothetical modelling are antici-
pated. Moreover, the DO-IT Registry intends to extend the
observation period if cooperation of the participating hos-
pitals and additional funding can be arranged.
Conclusion
At present, the indication for primary prevention defibril-
lators may not be optimal. Many patients do not receive
appropriate ICD therapy, but are at risk of inappropriate
shocks, device complications, or die without ever needing
their ICD. The DO-IT Registry is a large nationwide cohort,
consisting of patients receiving ICDs for primary prevention
of SCD. Despite the limitations, we expect that the DO-IT
Registry will identify subgroups of patients who will not,
or not yet, sufficiently benefit from ICD implantation for
primary prevention. We also expect that the registry will
provide results regarding the costs and budget impact of
targeted supply of primary preventions ICDs. Because of
real-life data, the findings of this study should be represen-
tative and are likely to affect the current risk stratification
of SCD.
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